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Abstract
Many Canadian cities are experiencing ongoing infectious disease and overdose epidemics among
injection drug users (IDU). These health concerns have recently been exacerbated by the
increasing availability and use of methamphetamine. The challenges of reducing health-related
harms among IDU have led to an increased recognition that strategies to prevent initiation into
injection drug use must receive renewed focus. In an effort to better explore the factors that may
protect against or facilitate entry into injection drug use, the At Risk Youth Study (ARYS) has
recently been initiated in Vancouver, Canada. The local setting is unique due to the significant
infrastructure that has been put in place to reduce HIV transmission among active IDU. The ARYS
study will seek to examine the impact of these programs, if any, on non-injection drug users. In
addition, Vancouver has been the site of widespread use of methamphetamine in general and has
seen a substantial increase in the use of crystal methamphetamine among street youth. Hence, the
ARYS cohort is well positioned to examine the harms associated with methamphetamine use,
including its potential role in facilitating initiation into injection drug use. This paper provides some
background on the epidemiology of illicit drug use among street youth in North America and
outlines the methodology of ARYS, a prospective cohort study of street youth in Vancouver,
Canada.
Background
It is estimated that approximately 340,000 Americans [1]
and 100,000 Canadians are current injection drug users
(IDU) [2]. Injection drug use can lead to overdose, infec-
tious disease, loss of social and economic functioning and
extensive engagement in criminal activity. In addition to
the morbidity and mortality associated with infectious
diseases [3], overdose fatalities (usually opioid) among
IDU have been a leading cause of death within the general
population in many urban areas in North America in
recent years [4,5], including British Columbia, Canada,
where approximately one overdose death per day was
recorded throughout the late 1990s [6]. At a societal level,
injection drug use has created public health and fiscal cri-
ses, with multiple costs to public health care and auxiliary
services as well as the welfare and criminal systems [7-9].
Costs associated with treatment of human immunodefi-
ciency virus (HIV) and hepatitis C virus (HCV) infection
are also high [10]. In recent years, injection drug use has
been estimated to account for approximately 25% of new
HIV infections and 63% of new HCV infections in Can-
ada, with similar rates observed in the US [11,12]. In Van-
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couver, an explosive outbreak of HIV infection was
documented among IDU during the mid- to late-1990s,
characterized by an HIV incidence rate of 18 per 100 per-
son-years in 1997, one of the highest rates ever reported
in the developed world [13].
Recent reports of increasing injection drug use and high-
risk behavior by street youth in North America highlight
the growing risk of HIV transmission among younger age
groups and the urgent need to evaluate and inform pri-
mary prevention strategies among this population [14].
Street youth are particularly vulnerable to experiencing
health-related harms for a variety of reasons. These
include: lack of education about drug use, sexual health
risks; sexual and physical violence; poverty and neglect;
and precarious living conditions, either on the street or in
risky relationships, or both [15,16]. Not surprisingly,
injection drug use has become a growing problem among
this population. In the US, estimates of the prevalence of
injection drug use among street youth range from 30% to
40% [17-19], while a national study from the US found
approximately 28% of street youth and a further 10% of
youths living in shelters had participated in prostitution
[20]. Estimates of the number of street youth in Canada
have ranged as high as 150,000 [21], with injection drug
use reported by 38% and 54% of these individuals in Van-
couver [22] and Montreal [23], respectively. As a conse-
quence, street youth are increasingly recognized as being
among the highest at risk of those sub-populations at risk
for HIV and HCV infection.
Studies of factors associated with initiation of injection
drug use have suggested that close friends introduce the
majority of both males and females to injection drug use
[24,25]. The mean age of individuals initiating injection
ranges from 16 to 18 years, and the "introducer" is typi-
cally an IDU several years older [24-26]. Roy et al. found
that among Montreal street youth, more girls than boys
required assistance injecting and were less likely to use a
clean needle. Further, although a high proportion of new
initiates (84%) did inject with a clean needle, only 62%
used clean drug preparation equipment [23]. More
recently, prospective studies of youth transitioning from
non-injection drug use to injection drug use have identi-
fied a number of independent predictors for initiation of
injection [15,27,28]. Fuller et al. identified race other than
African American, exclusive crack smoking just prior to
initiating, smoking marijuana, high school dropout, and
sex trading during the year prior to transition, particularly
among young females, as correlates of transition from
non-injection to injection drug use in a cohort of young
high-risk drug users in Baltimore [27,28]. Roy et al. have
reported from a cohort study in Montreal that: having
been homeless; being under 18 years of age; being tat-
tooed; recent use of heroin, hallucinogens, cocaine, crack,
or freebase; being female with an IDU friend; and having
ever experienced extra-familial sexual abuse were all asso-
ciated with initiation of injection drug use by street youth
[15].
Nevertheless, large numbers of street youth exhibit many
of the above risk factors and do not transition into injec-
tion drug use [22,29]. As such, many questions remain
with regard to why some drug users transition into injec-
tion drug use and some do not [30]. In particular, there is
uncertainty regarding other factors that may facilitate ini-
tiation into injection drug use, such as the precise roles of
injection drug users in one's social network [31,32]. The
role of expanded access to syringes, in settings where
syringe exchange has become decentralized, has also not
been explored.
Although it is well documented that the environment,
social networks, health policy, and accessibility of inter-
ventions may contribute to or diminish the risk of HIV
and HCV infection [10,13,33,34], published data about
macro-level risk factors associated with initiation of drug
injection are scarce. Vancouver has recently initiated sev-
eral secondary prevention programs aimed at reducing
HIV incidence rates, including a large decentralized nee-
dle distribution program with a flexible exchange policy
and two medically supervised injecting clinics, yet no pro-
grams are in place to evaluate the impact of these policies
on street youth [35]. In addition, in recent years, evidence
has suggested that the use of methamphetamine has
grown in western Canada, with Vancouver being the pri-
mary site of this increase. Not surprisingly, methamphet-
amine is commonly used by Vancouver street youth, and
the health-related harms associated with this practice
remain under-investigated.
In light of the above concerns, and the fact that infectious
diseases and other harms persist despite HIV prevention
programming targeted towards injection drug users, it has
recently been argued that the injection-related infection
risk hierarchy should be updated so that the prevention of
injection drug use is given greater priority [31,32]. Con-
sistent with this call, a cohort of street youth has been ini-
tiated in Vancouver, Canada. Known as the At Risk Youth
Study (ARYS, pronounced 'arise'), the study will seek to
examine the impact of the local decentralized syringe dis-
tribution scheme and supervised injecting sites on the
rates of initiation of injection drug use. The working
hypothesis is that knowledge of and exposure to harm
reduction programs among non-injecting youth will not
be associated with increased rates of initiation into injec-
tion drug use. The ARYS study will also seek to examine
the impact of methamphetamine use on various health-
related harms, as well as the potential role of metham-
phetamine use in transitioning into injection drug use. InHarm Reduction Journal 2006, 3:18 http://www.harmreductionjournal.com/content/3/1/18
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this case, the working hypothesis is that smoked metham-
phetamine will be associated with subsequent initiation
into injection drug use. In keeping with recent develop-
ments related to improving reporting quality of non-ran-
domized evaluations of behavioral and public health
interventions [36], this paper describes the methodology
being employed in the ARYS study to investigate risk fac-
tors for initiation into injection drug use as well as poten-
tial health-related harms of methamphetamine use.
Methods
Recruitment and follow-up
The recruitment strategy for ARYS involves standard tech-
niques for reaching hidden populations, and recruitment
will be conducted from the city's streets and from youth
agencies and services [37-39]. Since there are no registries
from which to draw street youth, the sample can be
viewed as a convenience sample, although major efforts
are being undertaken to try to maximize the representa-
tiveness of the sample. This includes extensive street-
based outreach, including outreach during the nighttime,
and efforts to have street youth recruit their peers. Out-
reach has also been systematically undertaken in a range
of neighborhoods around the city where street youth are
known to congregate.
After initial contact is made, the nature of the study is
explained and informed consent is offered to those who
wish to enroll. Although these recruitment techniques are
inferior to random recruitment methods, random recruit-
ment of street youth was viewed to be impractical in our
setting, and we are unaware of any large prospective study
of street youth that has employed these methods. Eligibil-
ity criteria include age (14 to 26 years) and use of drugs
other than marijuana in the past 30 days. Eligibility is not
restricted to those youth who have already begun inject-
ing, and although ORALscreen drug test kits are being
used to assess illicit drug use levels at baseline, this screen
will not be used to exclude potential enrollees.
Data collection procedures for the ARYS cohort are similar
to other prospective cohort studies of illicit drug users
whereby individuals provide a baseline blood sample for
measurement of HIV and hepatitis C (HCV) antibodies
and complete an interviewer-administered questionnaire.
Pre- and post-test counseling and referral to health serv-
ices are provided as part of the study. To enable high rates
of follow-up, contact information is obtained and indi-
viduals are requested to return to the study site every six
months for the duration of the study, at which time blood
is again sampled for evaluation of HIV and HCV incidence
and a detailed follow-up questionnaire is administered. A
five-dollar incentive is also offered to youth to return after
three months to check in and update their contact infor-
mation, and thus far the majority of youth have checked
in at the three-month mark. In addition, the vast majority
of youth who have enrolled to date have provided email
addresses for follow-up purposes.
Although it was expected at the outset that follow-up with
this particular population would be challenging, it is
anticipated that these strategies may prove invaluable in
ensuring high rates of follow-up despite the issues of
mobility common among street youth.
Outcome ascertainment
Outcome ascertainment for the ARYS cohort will involve
blood testing, clinical evaluation of needle tracks, and
self-reported behavioral data obtained through the inter-
viewer-administered questionnaire. In addition, the local
setting is unique because of the availability of confidential
record linkages made possible through Canada's universal
healthcare system. Specifically, administrative databases
create an opportunity for the accurate ascertainment of
key measures, including emergency room and hospital
use, medication use, and contact with various harm reduc-
tion services, including the city's supervised injecting facil-
ity. These linkages have several advantages, since self-
reported health service use has been shown to be subject
to socially desirable responding [40].
Although many youth-specific indicators have had to be
developed, the survey instrument for the ARYS cohort is
largely based on the scales that have been developed as
part of the Vancouver Injection Drug Users Study
(VIDUS), a prospective cohort study of IDU that has been
described in detail previously [13,41-43]. The survey
instruments have been intentionally coordinated to facil-
itate the examination of the natural history of injection
drug use through to adulthood. Both surveys include sec-
tions on sources of income, non-injection and injection
drug use (including overdose and binging), interactions
with police, incarceration, sexual activity, drug and alco-
hol treatment, violence, and nutritional needs. Both sur-
veys also include standardized measures for depression
(Centre for Epidemiologic Studies Depression Scale [44])
and childhood trauma (Childhood Trauma Question-
naire [45,46]), as well as HIV knowledge scales [47] and a
non-standardized self-efficacy scale to evaluate self-effi-
cacy to avoid injection drug use. The youth survey also
includes sections on educational background and expo-
sure to injection drug use. The coordination of survey
instruments allows us to seek to explore the relationship
between established injectors and new initiates into injec-
tion drug use.
Additional data sources
The above prospective cohort data will be augmented by
a number of other data sources. First, quantitative activi-
ties of the ARYS cohort will be informed by a newly devel-Harm Reduction Journal 2006, 3:18 http://www.harmreductionjournal.com/content/3/1/18
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oped qualitative research program which will involve in-
depth qualitative interviews with street youth to further
explore areas of interest. For instance, street youth who
transition into injection drug use during follow-up will be
targeted for qualitative interviews so that the circum-
stances of initiation into injection drug use can be further
explored. Second, there will also be an active ethno-
graphic research team who will undertake field observa-
tions of drug use behaviors among street youth in natural
settings. When making observations and conducting
unstructured interviews in natural settings, study staff will
use a verbal script to inform potential participants about
the research, its purpose, and the risks involved. We will
also obtain verbal informed consent before observing and
recording data in the natural settings of parks, streets, and
alleyways where drug consumption activities are occur-
ring and where street youth congregate. In instances where
street youth express that they are not willing to be
observed or participate, the researcher will remove him/
herself from the immediate vicinity and attempt to engage
with street youth in another locale. Individuals participat-
ing in unstructured qualitative interviews go through a
similar informed consent process before interviews are
undertaken and field notes are recorded.
Results and discussion
Enrollment into ARYS began in October 2005, and
approximately 324 youth have been recruited to date. Pre-
liminary evaluation of the cohort shows that participants
are approximately 72% male, 25% Aboriginal, and the
median age is 22 (inter-quartile range is 21–24). Notably,
50% of all participants report either currently being or
having been injection drug users.
Unique ethical issues relating to methodology arise when
working with a cohort that includes legal minors. Because
one of the objectives of the study is to expand our current
understanding of the relationship between childhood sex-
ual and physical abuse and initiation of injection drug
use, questions of that nature are included on the question-
naire. However, because of the legal duty to report abuse
of persons under the age of 19 in our jurisdiction (British
Columbia), researchers are placed in the position of hav-
ing to carry out that legal duty in the course of collecting
these data from minors. This limitation to confidentiality
is spelled out in the consent form, and participants are
assured that they can refuse to answer questions about
abuse (or any other topic) if they choose. When partici-
pants under age 19 choose to disclose abuse in the course
of answering survey questions, interviewers are trained to
follow up on the duty to report. All efforts are made to
report with the participant's consent and full knowledge,
and participants are offered referrals to free and available
community counseling services. Questions about abuse
are situated within the nurse's questionnaire, as it was felt
that participants would be more comfortable disclosing
and participating in reporting the abuse with an experi-
enced community health nurse. Further, two of the study's
investigators hold doctoral degrees in counseling psychol-
ogy and are available for clinical supervision when disclo-
sure of abuse occurs. Extensive consultation with the
government ministry responsible for investigating reports
of abuse occurred before the study commenced, as well as
with the chair of the research ethics board prior to submit-
ting the application for ethics approval of the study. The
challenge in terms of methodology is to collect these
important data from participants within a research proto-
col that satisfies the legal duty to report abuse of minors
and ensures a standard of care in the process.
Conclusion
In summary, the recent reports of increasing injection
drug use and high-risk behavior by street youth in North
America highlight the growing risk of HIV transmission
among younger age groups and the urgent need to evalu-
ate and inform primary prevention strategies within this
population [14]. At present, many questions remain with
regard to why some drug users transition into injection
drug use and some do not [30], and it has recently been
argued that the injection-related infection risk hierarchy
should be updated so that the importance of prevention
of injection drug use is emphasized [31,32].
Vancouver, Canada, has recently initiated several second-
ary prevention programs, including a large decentralized
needle distribution program as well as two medically
supervised injecting clinics, aimed at reducing HIV inci-
dence rates among active injection drug users [35]. In
addition, the city has experienced a substantial increase in
methamphetamine use among street youth. In response
to the above issues, the ARYS cohort has been developed
to examine risk factors for initiation into injection drug
use and the harms of methamphetamine use among street
youth in this environment. Using the methodology
described above, recruitment was initiated in October
2005, and initial reports from the ARYS cohort are
expected in the summer of 2006.
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